Summary
Merck & Co., Inc.'s 2014 10-K filing reveals a year of strategic transformation, marked by a 4% decline in sales to $42.2 billion, largely attributed to product divestitures, including the significant sale of its Consumer Care segment, and the loss of market exclusivity for several key products. Despite the revenue dip, the company achieved several important product approvals, including Keytruda for advanced melanoma and Gardasil 9 for HPV prevention, signaling a strong focus on innovation and future growth drivers. The company also made significant pipeline advancements and strategic acquisitions, notably the acquisition of Cubist Pharmaceuticals to bolster its infectious disease portfolio. Restructuring efforts are progressing well, aiming for substantial cost savings by the end of 2015. Management remains focused on prioritizing R&D and commercial resources toward areas with high unmet medical needs and significant growth potential, demonstrating a commitment to long-term value creation despite near-term revenue headwinds from divestitures and patent expirations.
Financial Highlights
54 data points| Revenue | $42.24B |
| Cost of Revenue | $16.77B |
| Gross Profit | $25.47B |
| R&D Expenses | $7.18B |
| SG&A Expenses | $11.61B |
| Interest Expense | $732.00M |
| Net Income | $11.92B |
| EPS (Basic) | $4.12 |
| EPS (Diluted) | $4.07 |
| Shares Outstanding (Basic) | 2.89B |
| Shares Outstanding (Diluted) | 2.93B |
Key Highlights
- 1Merck divested its Consumer Care segment in October 2014, contributing to a 4% decrease in overall sales, which totaled $42.2 billion for the year.
- 2The company achieved significant product approvals in 2014, including Keytruda for advanced melanoma, Belsomra for insomnia, and Gardasil 9, a nine-valent HPV vaccine.
- 3Merck strengthened its R&D pipeline and therapeutic focus through acquisitions, including Idenix Pharmaceuticals (HCV) and OncoEthix (oncology), and announced the acquisition of Cubist Pharmaceuticals (infectious diseases) which closed in January 2015.
- 4Key therapeutic areas of focus for R&D include cancer, hepatitis C, cardiometabolic disease, resistant microbial infections, and Alzheimer's disease.
- 5Global restructuring programs are on track to achieve significant cost savings, with an expectation of annual net cost savings of $2.0 billion from the 2013 program by the end of 2015.
- 6The company returned nearly $13 billion to shareholders in 2014 through dividends and share repurchases, underscoring a commitment to capital return.
- 7The TECOS trial for sitagliptin (Januvia/Janumet) was nearing completion, with results expected in mid-2015, which could materially impact sales of the company's largest franchise.